The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit challenging the agency’s longstanding definition of “patient” under the 340B Drug Pricing Program.

The AHA argued that AbbVie is attempting to bypass the 340B program’s required audit and administrative dispute resolution processes and use litigation to change established program rules. The association said that HHS’ interpretation of “patient” is consistent with the 340B statute and allowing the case to proceed could deprive hospitals of due process protections guaranteed under the law.

Joining the AHA in the brief were America’s Essential Hospitals, the Children’s Hospital Association, the Association of American Medical Colleges and the American Society of Health-System Pharmacists.

Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…
Perspective
Public
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…